Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME1788)
DME Name Beta-glucuronidase (uidA), Escherichia coli DME Info
UniProt ID
BGLR_ECOLI
EC Number    EC: 3.2.1.31     (Click to Show/Hide the Complete EC Tree)
Hydrolases
Glycosylase
O/S-glycosyl compound glycosidase
EC: 3.2.1.31
Lineage    Species: Escherichia coli     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Escherichia
Species: Escherichia coli
Subspecies: Escherichia coli K-12
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      Drug co-metabolism
               Cometabolized drug: Irinotecan hydrochloride Click to Show/Hide the Full List of HOSPPI:        7 HOSPPI
                            Carboxylesterase 1 (CES1) Click to Show/Hide the Cometabolization Info
DME ID DME0054 DME Info
Uniprot ID
EST1_HUMAN
Interaction Name CES1-uidA interaction [1], [2]
Description The interaction, between human Carboxylesterase 1 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Carboxylesterase 2 (CES2) Click to Show/Hide the Cometabolization Info
DME ID DME0057 DME Info
Uniprot ID
EST2_HUMAN
Interaction Name CES2-uidA interaction [1], [3]
Description The interaction, between human Carboxylesterase 2 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Carboxylesterase 3 (CES3) Click to Show/Hide the Cometabolization Info
DME ID DME0056 DME Info
Uniprot ID
EST3_HUMAN
Interaction Name CES3-uidA interaction [1], [3]
Description The interaction, between human Carboxylesterase 3 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2B6 (CYP2B6) Click to Show/Hide the Cometabolization Info
DME ID DME0020 DME Info
Uniprot ID
CP2B6_HUMAN
Interaction Name CYP2B6-uidA interaction [1], [6]
Description The interaction, between human Cytochrome P450 2B6 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A4 (CYP3A4) Click to Show/Hide the Cometabolization Info
DME ID DME0001 DME Info
Uniprot ID
CP3A4_HUMAN
Interaction Name CYP3A4-uidA interaction [1], [2]
Description The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A5 (CYP3A5) Click to Show/Hide the Cometabolization Info
DME ID DME0012 DME Info
Uniprot ID
CP3A5_HUMAN
Interaction Name CYP3A5-uidA interaction [1], [8]
Description The interaction, between human Cytochrome P450 3A5 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A7 (CYP3A7) Click to Show/Hide the Cometabolization Info
DME ID DME0015 DME Info
Uniprot ID
CP3A7_HUMAN
Interaction Name CYP3A7-uidA interaction [1], []
Description The interaction, between human Cytochrome P450 3A7 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
               Cometabolized drug: Conjugated estrogens Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                            Cytochrome P450 1A2 (CYP1A2) Click to Show/Hide the Cometabolization Info
DME ID DME0003 DME Info
Uniprot ID
CP1A2_HUMAN
Interaction Name CYP1A2-uidA interaction [4], [5]
Description The interaction, between human Cytochrome P450 1A2 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Conjugated estrogens, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A4 (CYP3A4) Click to Show/Hide the Cometabolization Info
DME ID DME0001 DME Info
Uniprot ID
CP3A4_HUMAN
Interaction Name CYP3A4-uidA interaction [4], [7]
Description The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Conjugated estrogens, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
               Cometabolized drug: SN-38 Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                            UDP-glucuronosyltransferase 1A1 (UGT1A1) Click to Show/Hide the Cometabolization Info
DME ID DME0004 DME Info
Uniprot ID
UD11_HUMAN
Interaction Name UGT1A1-uidA interaction [9]
Description The interaction, between human UDP-glucuronosyltransferase 1A1 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug SN-38, is reported to cause an adverse drug reaction.
References
1 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
2 Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
3 Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
4 Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
5 Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006 Nov;46(11):1299-307.
6 Drugs that may have potential CYP2B6 interactions.
7 Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115.
8 Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
9 Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.